- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
New Data at American Society of Hematology (ASH) Annual Meeting Will Offer Important Insights into Safe and Efficacious Use of XARELTO®
XARELTO® is the Most Prescribed Novel Oral Anticoagulant in the U.S. Market Today
OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
OLYSIO™is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease
Janssen Oncology Data to be Presented at 2013 American Society of Hematology (ASH) Annual Meeting
Findings Highlight Company’s Growing Hematologic Area of Focus, Including Ibrutinib, Siltuximab and Daratumumab
IMBRUVICA™ (ibrutinib) Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy
Single-agent oral therapy is one of the first medications to be approved via the U.S. Food and Drug Administration’s Breakthrough Therapy Designation Pathway
New Marketing Authorisation Application Submitted to EMA for Ibrutinib for the Treatment of Two Forms of Blood Cancer
The submission is for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and mantle cell lymphoma (MCL), two difficult-to-treat diseases
New STELARA® Data Show Inhibition Of Joint Destruction In Patients With Active Psoriatic Arthritis
Integrated Analysis of Two Pivotal Phase 3 Studies Showed STELARA Inhibited the Progression of Structural Damage at Week 24, and Demonstrated Continued Inhibition through Two Years